Korsana Biosciences Financial Statements
NASDAQ: KRSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Korsana Biosciences revenue and earnings
In fiscal 2025, Korsana Biosciences generated $2.1 million in revenue, up 3.7% from fiscal 2024, its 2nd consecutive year of revenue growth. Korsana Biosciences reported a net loss of $3.5 million, compared with a loss of $3.1 million a year earlier. Operating margin was -239.8%.
Diluted earnings per share came in at -$1.11. Over the last 5 fiscal years, KRSA's revenue has grown at a -2.0% compound annual rate (a contraction).
Summary generated from market data by MetaCap's automated system. Methodology
Korsana Biosciences income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.07M | 2.00M | 0 | 297.00K | 3.94M | 2.30M | 4.51M | — |
| Revenue growth (YoY) | +3.70% | — | -100.00% | -92.47% | +71.69% | -49.06% | — | — |
| Operating Expenses | 7.05M | 5.63M | 12.95M | 18.84M | 59.14M | 83.56M | 129.54M | 115.25M |
| Research & Development | 959.00K | 286.00K | 1.51M | 5.98M | 37.64M | 56.41M | 95.14M | 87.72M |
| Operating Income | -4.97M | -3.63M | -12.95M | -18.54M | -55.20M | -81.27M | -125.04M | -115.25M |
| Other Income (Expense) | 1.45M | 571.00K | 358.00K | 294.00K | -16.00K | 588.00K | — | — |
| Pretax Income | -3.53M | -3.06M | -5.26M | -44.08M | -51.65M | -122.41M | -122.41M | -115.25M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -3.53M | -3.06M | -5.26M | -44.08M | -51.65M | -77.80M | -123.01M | -115.25M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.11 | -1.21 | -2.25 | -20.28 | -1.32 | -2.56 | -4.49 | -4.21 |
| EPS (Diluted) | -1.11 | -1.21 | -2.25 | -20.28 | -1.32 | -2.56 | -4.49 | -4.21 |
| Shares Outstanding (Basic) | 3.18M | 2.52M | 2.34M | 2.17M | 39.14M | 30.40M | 27.38M | 27.38K |
| Shares Outstanding (Diluted) | 3.18M | 2.52M | 2.34M | 2.17M | 39.14M | 30.40M | 27.38M | 27.38K |
| EBITDA | — | — | -12.95M | -18.48M | -54.72M | -78.97M | -122.34M | -113.72M |
| Operating Margin | -239.78% | -181.40% | — | -6242.42% | -1400.18% | -3539.42% | -2774.28% | — |
| Net Margin | -170.11% | -152.85% | — | -14841.08% | -1310.17% | -3388.59% | -2729.27% | — |
This table shows 8 annual periods of Korsana Biosciences's income statement, from FY 2025 back to FY 2018, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow KRSA's reporting calendar. What is a income statement?